Bosutinib Impurity 31

Bosutinib Impurity 31 - Names and Identifiers

Name	7-(3-Chloropropoxy)-4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxyquinoline-3-carbonitrile
Synonyms	Bosutinib Impurity 31 Bosutinib Impurity 24 Bosutinib intermediate 7-(3-chloropropoxy)-4-(2,4-dichloro-5-methoxyanilino)-6-methoxyquinoline-3-carbonitrile 7-(3-Chloropropoxy)-4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxyquinoline-3-carbonitrile 7-(3-Chloropropoxy)-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-3-quinolinecarbonitrile 7-(3-CHLORO-PROPOXY)-4-(2,4-DICHLORO-5-METHOXY-PHENYLAMINO)-6-METHOXY-QUINOLINE-3-CARBONITRILE 3-Quinolinecarbonitrile, 7-(3-chloropropoxy)-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-
CAS	380844-49-5

Bosutinib Impurity 31 - Physico-chemical Properties

Molecular Formula	C21H18Cl3N3O3
Molar Mass	466.74
Density	1.43
Melting Point	183-186℃
Boling Point	585.6±50.0 °C(Predicted)
Solubility	Chloroform (Slightly, Sonicated), DMSO (Slightly)
Appearance	Solid
Color	Pale Yellow to Light Yellow
pKa	3.71±0.50(Predicted)
Storage Condition	under inert gas (nitrogen or Argon) at 2–8 °C

Bosutinib Impurity 31 - Reference Information

Introduction

7-(3-chloropropoxy)-4-[(2, 4-dichloro-5-methoxyphenyl) amino]-6-methoxy-3-cyanoquinoline is an intermediate of Besutinib. Besulitinib is developed by Wyeth Pharmaceuticals (Wyeth
Pharmaceuticals). Besulitinib (bosutinib) was approved by the European Union as an "orphan drug" in the treatment of chronic myeloid leukemia (CML) in September 2010.

Last Update：2024-04-09 15:16:36